The number of control, <i>Brca2</i> mutant and <i>Brca2</i>;<i>Trp53</i> mutant prostates analysed and their phenotype.

Brca2 homozygous mutant prostates (Brca2F/F;PBCre4) have hyperplasia (Hyp) at 10–14 months and LG PIN at 15–20 months. Brca2 homozygous Trp53 heterozygous mutant prostates (Brca2F/F;Trp53F/+;PBCre4) have hyperplasia and LG PIN at 10–14 months, and by 15–20 months have HG PIN. Brca2;Trp53 double homozygous mutant (Brca2F/F;Trp53F/F;PBCre4) prostates have hyperplasia at 6 months and LG PIN at 10–14 months, and by 15–19 months have a high incidence of LG PIN and HG PIN.